Combination treatment of IFNα2b and ribavirin in patients with chronic hepatitis C and persistently normal ALTs

被引：10

作者：

Erhardt, A

Behlen-Wilm, U

Adams, O

Donner, A

Heintges, T

Häussinger, D

机构：

[1] Univ Dusseldorf, Klin Gastroenterol Hepatol & Infektiol, D-40225 Dusseldorf, Germany

[2] Univ Dusseldorf, Inst Med Mikrobiol & Virol, D-40225 Dusseldorf, Germany

[3] Univ Dusseldorf, Inst Pathol, D-40225 Dusseldorf, Germany

来源：

DIGESTIVE DISEASES AND SCIENCES | 2003年 / 48卷 / 05期

关键词：

hepatitis C; ALT; interferon; ribavirin; treatment;

D O I：

10.1023/A:1023051613300

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Combination therapy of interferon-alpha(2b) and ribavirin was prospectively evaluated in 20 patients with chronic replicative hepatitis and persistently normal ALTs. Patients with normal ALTs on three or more occasions within 6 months received interferon-alpha(2b) 3 MU three times a week with ribavirin 1000-1200 mg everyday for 12 months and had a follow-up of 6 months. HCV genotype 1 was found in 16, and HCV genotype 2 or 3 in 4 patients. No patient experienced an ALT elevation during therapy. Ten of 20 patients (50%) cleared virus at the end of treatment. In an intent-to-treat analysis, a sustained virological response (SR) was achieved in 8 of 20 patients (40%). Nonresponse occurred in 5 patients. Relapse and breakthrough were seen in 2 patients each. Treatment was discontinued in 3 patients due to side effects. Interferon (IFN) ribavirin combination therapy is effective in patients with normal ALTs and appears superior to IFN monotherapy.

引用

页码：921 / 925

页数：5

共 30 条

[1]

[Anonymous], 1997, HEPATOLOGY, V26, pS2

[2]

*EAST INT CONS C H, 1999, J HEPATOL, V30, P956

[3] Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. [J].

Fried, MW ;

Shiffman, ML ;

Reddy, KR ;

Smith, C ;

Marinos, G ;

Goncales, FL ;

Haussinger, D ;

Diago, M ;

Carosi, G ;

Dhumeaux, D ;

Craxi, A ;

Lin, A ;

Hoffman, J ;

Yu, J .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (13) :975-982

[4] HISTOLOGICAL GRADING AND STAGING OF CHRONIC HEPATITIS [J].

ISHAK, K ;

BAPTISTA, A ;

BIANCHI, L ;

CALLEA, F ;

DEGROOTE, J ;

GUDAT, F ;

DENK, H ;

DESMET, V ;

KORB, G ;

MACSWEEN, RNM ;

PHILLIPS, MJ ;

PORTMANN, BG ;

POULSEN, H ;

SCHEUER, PJ ;

SCHMID, M ;

THALER, H .

JOURNAL OF HEPATOLOGY, 1995, 22 (06) :696-699

[5] Pilot study of interferon-α and ribavirin treatment in patients with chronic hepatitis C and normal transaminase values [J].

Lee, SS ;

Sherman, M .

JOURNAL OF VIRAL HEPATITIS, 2001, 8 (03) :202-205

[6] Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial [J].

Manns, MP ;

McHutchison, JG ;

Gordon, SC ;

Rustgi, VK ;

Shiffman, M ;

Reindollar, R ;

Goodman, ZD ;

Koury, K ;

Ling, MH ;

Albrecht, JK .

LANCET, 2001, 358 (9286) :958-965

[7] Therapy of hepatitis C: Patients with normal aminotransferase levels [J].

Marcellin, P ;

Levy, S ;

Erlinger, S .

HEPATOLOGY, 1997, 26 (03) :S133-S136

[8]

Marcellin P, 1999, Clin Liver Dis, V3, P843, DOI 10.1016/S1089-3261(05)70242-7

[9] Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity [J].

Mathurin, P ;

Moussalli, J ;

Cadranel, JF ;

Thibault, V ;

Charlotte, F ;

Dumouchel, P ;

Cazier, A ;

Huraux, JM ;

Devergie, B ;

Vidaud, M ;

Opolon, P ;

Poynard, T .

HEPATOLOGY, 1998, 27 (03) :868-872

[10] Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C [J].

McHutchison, JG ;

Gordon, SC ;

Schiff, ER ;

Shiffman, ML ;

Lee, WM ;

Rustgi, VK ;

Goodman, ZD ;

Ling, MH ;

Cort, S ;

Albrecht, JK .

NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (21) :1485-1492

← 1 2 3 →